Precision Biosciences 3Q 2026: Revenue $0 Net loss $7.6M, EPS $(0.28) — 10-Q Summary

What happened

Precision Biosciences reported third-quarter 2026 revenue of $0 versus $13K a year earlier, and a net loss of $7.6M versus $21.8M. The narrower loss included a $12.7M non-cash gain from changes in warrant fair value, and diluted EPS was $(0.28).

Confirmed

Global impact / market context

The company earned no product revenue this quarter, so its cash comes from partners and licensing deals. The smaller loss was mostly an accounting gain, not better operations, which means investors should watch how long its cash can fund costly gene-editing trials.

Analyst inference

Early-stage gene-editing firms often show no revenue while funding trials through partnerships and share issuance. Because the reported improvement came from a non-cash warrant fair-value gain, which means an accounting adjustment rather than cash received, the underlying cash use and trial progress matter more than the headline loss.

Analyst inference

What to watch

1. Initial safety data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD are targeted by year-end 2026, and additional trial sites are now active. Confirmed
2. Watch whether management funds trial costs through new partnership payments or share sales, since revenue was zero this quarter and cash needs continue. Proposed
3. Track nine-month collaboration revenue of $10.8M, because losing a partner like TG Therapeutics or the agriculture gene-editing partner would remove the main reported revenue source. Analyst inference

Evidence

• Original source link unavailable